Vimarsana
Biggest News Aggregation in the World

Page 3 - Veronica Eames News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Veronica Eames. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Veronica Eames Today - Breaking & Trending Today

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data - Vimarsana News

Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data

November 16 Event to feature KOL perspective on Emerging HBV TherapiesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 -- Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on...

Cidara Therapeutics : Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Form 8-K -November 02, 2023 at 04:25 pm EDT - Vimarsana News

Cidara Therapeutics : Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Form 8-K -November 02, 2023 at 04:25 pm EDT

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results SAN DIEGO, November 2, 2023- Cidara Therapeutics, Inc. , a biotechnology company...

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Vimarsana News

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company focused on developing targeted th...

Aligos Therapeutics Announces $92 Million Private Placement Financing - Vimarsana News

Aligos Therapeutics Announces $92 Million Private Placement Financing

Proceeds expected to fund the following:

Cidara Therapeutics and Mundipharma receive positive CHMP - Vimarsana News

Cidara Therapeutics and Mundipharma receive positive CHMP

The opinion was based on positive results from the pivotal ReSTORE Phase III clinical trial and supported by the STRIVE Phase II clinical trials and...